- Home
- GMAB vs TKO Comparison
GMAB vs TKO Comparison
Compare GMAB & TKO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- TKO
- Stock Information
- Founded
- GMAB 1999
- TKO 1980
- Country
- GMAB Denmark
- TKO United States
- Employees
- GMAB N/A
- TKO N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- TKO
- Sector
- GMAB Health Care
- TKO
- Exchange
- GMAB Nasdaq
- TKO Nasdaq
- Market Cap
- GMAB 17.4B
- TKO 15.6B
- IPO Year
- GMAB N/A
- TKO N/A
- Fundamental
- Price
- GMAB $29.93
- TKO $187.69
- Analyst Decision
- GMAB Strong Buy
- TKO Strong Buy
- Analyst Count
- GMAB 7
- TKO 18
- Target Price
- GMAB $41.17
- TKO $209.53
- AVG Volume (30 Days)
- GMAB 3.1M
- TKO 1.3M
- Earning Date
- GMAB 11-06-2025
- TKO 11-05-2025
- Dividend Yield
- GMAB N/A
- TKO 0.81%
- EPS Growth
- GMAB 77.72
- TKO N/A
- EPS
- GMAB 21.62
- TKO 1.78
- Revenue
- GMAB $3,646,881,232.00
- TKO $2,965,944,000.00
- Revenue This Year
- GMAB $24.25
- TKO $69.02
- Revenue Next Year
- GMAB $16.29
- TKO $27.62
- P/E Ratio
- GMAB $13.36
- TKO $104.83
- Revenue Growth
- GMAB 32.97
- TKO N/A
- 52 Week Low
- GMAB $17.24
- TKO $114.01
- 52 Week High
- GMAB $33.65
- TKO $212.49
- Technical
- Relative Strength Index (RSI)
- GMAB 46.39
- TKO 42.88
- Support Level
- GMAB $29.57
- TKO $184.28
- Resistance Level
- GMAB $30.24
- TKO $191.36
- Average True Range (ATR)
- GMAB 0.67
- TKO 4.35
- MACD
- GMAB -0.58
- TKO -0.76
- Stochastic Oscillator
- GMAB 11.11
- TKO 17.95
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About TKO TKO Group Holdings Inc.
TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events, sponsorship, and consumer products licensing agreements of UFC-branded products.